Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SG-3-06686
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SG-3-06686, enhances effector T cell migration to improve the immune system’s activity against tumors and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment.
Product Name : SG-3-06686
Product Type : Peptide
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : SG-3-06686
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SG-5-00455
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD).
Product Name : SG-5-00455
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : SG-5-00455
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SG-5-00455
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model.
Product Name : SG-5-00455
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : SG-5-00455
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SG-3-0020
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SG-3-0020 enhanced PD-1 expression and IFNg secretion by anti-CD3 activated human T cells in vitro provide a strong rationale for SG-3-0020's potential future use in cancer therapies.
Product Name : SG-3-0020
Product Type : Peptide
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : SG-3-0020
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Gilead Sciences
Deal Size : $1,538.0 million
Deal Type : Collaboration
Details : Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $38.0 million
June 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Gilead Sciences
Deal Size : $1,538.0 million
Deal Type : Collaboration